BB Biotech

From Wikipedia, the free encyclopedia
Jump to: navigation, search
BB Biotech AG
Aktiengesellschaft
Traded as SIXBION, FWBBBZA
Industry Investments
Founded Schaffhausen, Switzerland (9 November 1993 (9 November 1993))
Headquarters Küsnacht, Switzerland
Key people
Erich Hunziker (Chairman)
Products Investment in biotechnology companies
CHF 391 million (2012)[1]
Profit Increase (CHF 367.8 million) (2012)[2]
Total assets CHF 1.3763 billion (2012)[1]
Total equity CHF 1.234 billion (2012)[1]
Website www.bbbiotech.ch

BB Biotech AG (Bank am Bellevue) is a Swiss investment company in the field of biotechnology. Since 1993 it is listed on the SIX Swiss Exchange, since 1997 on the German TecDAX and since 2000 on the Italian Borsa Italiana.[3]

At of March 31, 2015 the six largest holdings in the BB Biotech portfolio were (in order of value): a 10.7% stake in Celgene; 9.5% of Isis Pharmaceuticals; , 9.1% of Incyte, 7.3% of Gilead Sciences; 7.3% of Actelion; 4.6% of Agios Pharmaceuticals.

Company Figures[4][edit]

(figures in millions CHF) 2012 2013 2014
revenues 145,25 184,76 221,25
operating profit 368,60 932,22 1.469,31
Profit 367,83 931,83 1.470,14
Equity 1.234,01 2.118,87 3.492,53
Market capitalization 3.480

References[edit]

  1. ^ a b c "Annual Report 2012" (PDF). BB Biotech. Retrieved 29 November 2013. [permanent dead link]
  2. ^ "Annual Report 2010" (PDF). BB Biotech. Retrieved 13 March 2011. [permanent dead link]
  3. ^ "BB Biotech - Facts & Figures". BB Biotech. Retrieved 2013-11-28. 
  4. ^ finanzen.net Retrieved 1st of January 2016.

External links[edit]